Acute Intermittent Porphyria Market Set to Reach $6 Billion by 2029 with 6.3% Yearly Growth

How Are the key drivers contributing to the expansion of the acute intermittent porphyria market?
The increasing incidence of metabolic disorders is anticipated to spur the expansion of the acute intermittent porphyria market. Metabolic disorders, which are a set of conditions resulting from unusual chemical reactions in the body that hinder normal metabolic processes, can arise from genetic factors, lifestyle habits, environmental elements, and improved awareness as well as diagnosis procedures. The escalating figure of metabolic disorders is motivating the pharmaceutical industry to make investments in remedies for rare genetic conditions such as acute intermittent porphyria. For example, the Cleveland Clinic, a US-based nonprofit academic medical center, reported in December 2023 that metabolic disorders affecting genes are impacting around 1 in 1,000 to 2,500 births worldwide. Consequently, the surge in metabolic disorders is augmenting the growth of the acute intermittent porphyria market.

Get Your Acute Intermittent Porphyria Market Report Here:
https://www.thebusinessresearchcompany.com/report/acute-intermittent-porphyria-global-market-report

What growth opportunities are expected to drive the acute intermittent porphyria market's CAGR through 2034?
The value of the acute intermittent porphyria market has consistently increased in the past few years. Its projected growth is from $4.37 billion in 2024 to $4.66 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this growth throughout the historical period include the increasing expenditure in healthcare, expansion in the biopharmaceuticals market, a surge in the occurrence of genetic disorders, the broadening scope of telemedicine services, and an enhanced emphasis on early detection.

In the coming years, the market size for acute intermittent porphyria is anticipated to experience substantial growth, with a forecasted value of $5.96 billion by 2029, generated at a compound annual growth rate (CAGR) of 6.3%. Numerous elements contribute to this projected expansion, including a rise in acute intermittent porphyria cases, increasing awareness about rare diseases, patient advocacy growth, expanding genetic testing services, and favourable government policies. Furthermore, the market trend for the forecasted period includes the advancement in diagnostic methods, the emergence of innovative therapeutic options, increased investment in research and development, collaborations among pharmaceutical companies, and technological advancements in treatment.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19264&type=smp

What are the emerging trends shaping the future of the acute intermittent porphyria market?
The acute intermittent porphyria market is dominated by leading companies that are concentrating their efforts on the creation of novel products such as management tablets for acute intermittent porphyria, in order to offer improved services to their customers. These tablets provide an oral treatment to prevent and manage AIP symptoms and acute attacks. Alembic Pharmaceuticals Ltd, a pharmaceutical business based in India, received approval from the US Food & Drug Administration for its Chlorpromazine Hydrochloride Tablets USP in October 2023. These tablets, which come in various strengths of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, are utilized to manage psychosis symptoms and for the treatment of schizophrenia. Further, they are effective in controlling nausea and vomiting, reducing restlessness and unease prior to a surgery, and can be used alongside tetanus treatment. With specific reference to acute intermittent porphyria, these tablets manage the disease, control the manic symptoms in manic-depression, and offer relief from persistent hiccups.

Which growth-oriented segments of the acute intermittent porphyria market are leading the industry's development?
The acute intermittent porphyriamarket covered in this report is segmented -

1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis
2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments
3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:
1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test
2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test
3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test
4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test
5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19264

What regions are leading the charge in the acute intermittent porphyria market?
North America was the largest region in the acute intermittent porphyria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the acute intermittent porphyria market?
Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19264&type=smp

What Is Covered In The Acute Intermittent Porphyria Global Market Report?

•Market Size Forecast: Examine the acute intermittent porphyria market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the acute intermittent porphyria market for a structured understanding.
•Key Players Overview: Analyze major players in the acute intermittent porphyria market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the acute intermittent porphyria market.
•Segment Contributions: Evaluate how different segments drive overall growth in the acute intermittent porphyria market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the acute intermittent porphyria market.
•Industry Challenges: Identify potential risks and obstacles affecting the acute intermittent porphyria market.
•Competitive Landscape: Review strategic developments in the acute intermittent porphyria market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.